$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

$abeo Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016278 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$3.500M		$346.0K
YoY Change	250.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.021M	$3.997M	$4.224M
YoY Change	45.12%	-5.37%	-35.71%
% of Gross Profit
Research & Development	$8.523M	$8.041M	$10.55M
YoY Change	28.01%	-23.75%	46.26%
% of Gross Profit
Depreciation & Amortization	$615.0K	$661.0K	$811.0K
YoY Change	-20.44%	-18.5%	-1.1%
% of Gross Profit
Operating Expenses	$15.12M	$12.04M	$14.77M
YoY Change	67.84%	-18.49%	1.16%
Operating Profit	-$10.55M	-$12.04M	-$20.59M
YoY Change	31.79%	-41.54%
Interest Expense	$314.0K	$101.0K	-$200.0K
YoY Change	-0.95%	-150.5%	-85.82%
% of Operating Profit
Other Income/Expense, Net	-$6.414M	$2.668M	-$1.260M
YoY Change	5335.59%	-311.75%
Pretax Income	-$16.65M	-$9.107M	-$20.79M
YoY Change	100.77%	-56.2%	29.94%
Income Tax
% Of Pretax Income
Net Earnings	-$16.65M	-$9.107M	-$20.79M
YoY Change	100.77%	-56.2%	29.94%
Net Earnings / Revenue	-475.83%		-6008.96%
Basic Earnings Per Share	$0.92	-$0.54	-$3.80
Diluted Earnings Per Share	-$0.92	-$0.54	-$3.588M
COMMON SHARES
Basic Shares Outstanding	18.78M shares	17.71M shares	5.795M shares
Diluted Shares Outstanding	18.02M shares	16.90M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.77M	$40.36M	$31.32M
YoY Change	82.98%	28.9%	-63.92%
Cash & Equivalents	$6.225M	$4.680M	$20.33M
Short-Term Investments	$30.55M	$35.68M	$10.99M
Other Short-Term Assets	$1.539M	$1.961M	$7.889M
YoY Change	-79.01%	-75.14%	338.28%
Inventory
Prepaid Expenses
Receivables	$3.500M
Other Receivables	$2.227M	$519.0K	$0.00
Total Short-Term Assets	$44.04M	$42.84M	$39.20M
YoY Change	45.36%	9.28%	-55.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.404M	$5.298M	$15.95M
YoY Change	26.06%	-66.78%	-9.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$108.0K	$99.00K	$20.00K
YoY Change	440.0%	395.0%	-98.33%
Total Long-Term Assets	$9.512M	$10.50M	$15.97M
YoY Change	-34.05%	-34.24%	-69.76%
TOTAL ASSETS
Total Short-Term Assets	$44.04M	$42.84M	$39.20M
Total Long-Term Assets	$9.512M	$10.50M	$15.97M
Total Assets	$53.55M	$53.35M	$55.17M
YoY Change	19.75%	-3.31%	-60.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.477M	$2.857M	$1.601M
YoY Change	100.06%	78.45%	-35.96%
Accrued Expenses	$5.758M	$2.569M	$6.028M
YoY Change	8.01%	-57.38%	31.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.440M	$7.420M	$12.34M
YoY Change	-31.02%	-39.86%	-69.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$34.77M	$27.19M	$11.39M
YoY Change	17282.5%	138.63%	127.84%
Total Long-Term Liabilities	$34.77M	$27.19M	$11.39M
YoY Change	17282.5%	138.63%	83.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.440M	$7.420M	$12.34M
Total Long-Term Liabilities	$34.77M	$27.19M	$11.39M
Total Liabilities	$44.21M	$34.61M	$23.73M
YoY Change	79.45%	45.83%	-49.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$721.1M	-$704.4M
YoY Change	5.31%
Common Stock	$215.0K	$179.0K
YoY Change	-85.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.345M	$18.74M	$31.44M
YoY Change
Total Liabilities & Shareholders Equity	$53.55M	$53.35M	$55.17M
YoY Change	19.75%	-3.31%	-60.98%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$16.65M	-$9.107M	-$20.79M
YoY Change	100.77%	-56.2%	29.94%
Depreciation, Depletion And Amortization	$615.0K	$661.0K	$811.0K
YoY Change	-20.44%	-18.5%	-1.1%
Cash From Operating Activities	-$10.28M	-$11.70M	-$13.69M
YoY Change	14.1%	-14.52%	0.71%
INVESTING ACTIVITIES
Capital Expenditures	$32.00K	$218.0K	-$103.0K
YoY Change		-311.65%	-76.59%
Acquisitions
YoY Change
Other Investing Activities	$5.243M	$2.429M	$1.178M
YoY Change	-475.04%	106.2%	-88.0%
Cash From Investing Activities	$5.211M	$2.211M	$1.075M
YoY Change	-472.75%	105.67%	-88.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.618M	-$4.000K
YoY Change	-274.99%
NET CHANGE
Cash From Operating Activities	-10.28M	-$11.70M	-13.69M
Cash From Investing Activities	5.211M	$2.211M	1.075M
Cash From Financing Activities	6.618M	-$4.000K
Net Change In Cash	1.545M	-$9.537M	$0.00
YoY Change	-110.89%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$10.28M	-$11.70M	-$13.69M
Capital Expenditures	$32.00K	$218.0K	-$103.0K
Free Cash Flow	-$10.32M	-$11.92M	-$13.58M
YoY Change	14.46%	-12.26%	3.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2023Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2023Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2022Q1	abeo	Payments Made For Net Settlement Of Restricted Share Awards PaymentsMadeForNetSettlementOfRestrictedShareAwards		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2023Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative		usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000318306
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2023Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2023Q1	abeo	Impairment Of Constructioninprogress ImpairmentOfConstructioninprogress		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-15771
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ABEONA THERAPEUTICS INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-0221517
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	6555 Carnegie Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	4thFloor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cleveland
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	44103
CY2023Q1	dei	City Area Code CityAreaCode	(646)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	813-4701
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	ABEO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18778182	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4680000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14217000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	35684000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	37932000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	338000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	338000	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	519000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	188000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1623000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	424000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	42844000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	53099000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5298000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5741000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5104000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5331000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	99000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	43000	usd
CY2023Q1	us-gaap	Assets Assets	53345000	usd
CY2022Q4	us-gaap	Assets Assets	64214000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2857000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1811000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2569000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3991000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1789000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1773000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	205000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	204000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7420000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7779000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5530000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5854000	usd
CY2023Q1	abeo	Warrant Liabilities WarrantLiabilities	17392000	usd
CY2022Q4	abeo	Warrant Liabilities WarrantLiabilities	19657000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	34605000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	37453000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17929344	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17929344	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17719720	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17719720	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	179000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	177000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	723069000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	722049000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-704443000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-695336000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-65000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-129000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18740000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53345000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64214000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	346000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8041000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10545000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3997000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	84000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4224000	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1355000	usd
CY2022Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1561000	usd
CY2022Q1	abeo	Impairment Of Constructioninprogress ImpairmentOfConstructioninprogress	-3252000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	12038000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	20937000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12038000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20591000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	364000	usd
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	7000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	101000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	201000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2265000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1253000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	403000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-6000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22044000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.80
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16904024	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5795107	shares
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	64000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9043000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22047000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	770000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-4000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	256000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	64000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18740000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	42368000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	862000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22044000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	21183000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22044000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	661000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	811000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	770000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	862000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2265000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1253000	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1355000	usd
CY2022Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1561000	usd
CY2022Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3252000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	117000	usd
CY2023Q1	abeo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	2586000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	227000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	302000	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	100000	usd
CY2022Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	200000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	75000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1199000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-379000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	56000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-148000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-684000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4386000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1000	usd
CY2022Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-296000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11744000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13687000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	218000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	103000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7964000	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7487000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	10393000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	8665000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2211000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1075000	usd
CY2023Q1	abeo	Payments Made For Net Settlement Of Restricted Share Awards PaymentsMadeForNetSettlementOfRestrictedShareAwards	4000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9537000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12612000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14555000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38829000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5018000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26217000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4680000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20326000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5891000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5018000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26217000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8950000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1631000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	7319000	usd
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_84A_eus-gaap--BasisOfAccounting_zTanklxFKX66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zQV9dO0ASaC5">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made. These unaudited interim condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. Certain information that is normally required by U.S. GAAP has been condensed or omitted in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2022 condensed consolidated balance sheet was derived from the audited statements, but does not include all disclosures required by U.S. GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K/A for the year ended December 31, 2022, which was filed with the SEC on April 10, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	exchange ratio of 25-to-1 (the “Reverse Stock Split”).
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	40700000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11700000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P73M
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_z1OpwE9CJfil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zwa9pbwXd2B">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1253000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22044000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.80
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22047000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22044000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1253000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13687000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	696563000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	42368000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22044000	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	697426000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	21183000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10562522	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2150017	shares
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072	pure
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	35720000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	36000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	35684000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	38032000	usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	100000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	37932000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17838000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17620000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12540000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11879000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5298000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5741000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	700000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	800000	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3300000	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1400000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y8M19D
CY2022Q4	abeo	Warrant Liabilities WarrantLiabilities	19657000	usd
CY2023Q1	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	2265000	usd
CY2023Q1	abeo	Warrant Liabilities WarrantLiabilities	17392000	usd
CY2023Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zoOZIolmYCP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_827_zSKQipIhuAn">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zalUZ8VZdmkg" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_z470flO1PxUb" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, the Company recorded the payable due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zl5YzHlXiGS3" title="Interest rate stated percentage"><span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zqoARM7JdkIj" title="Interest rate stated percentage">9.6%</span></span>. The long-term portion due in <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zyGW18RlNmKg" title="Debt instrument maturity date"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zhlnW7PL95C2" title="Debt instrument maturity date">November 2024</span></span> was $<span id="xdx_90F_eus-gaap--LongTermDebt_iI_pn5n6_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zhzWNy8jMuC6" title="Long term debt">4.3</span> million and $<span id="xdx_904_eus-gaap--LongTermDebt_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_z7UWzbPorjW9" title="Long term debt">4.2</span> million as of March 31, 2023 and December 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	828000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	838000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2593000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1731000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1398000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2569000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3991000	usd
CY2022Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1600000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	415000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	472000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	39000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	96000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	18000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	21000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	472000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	589000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1338000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1815000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1572000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	811000	usd
CY2023Q1	abeo	Future Cash Receipts From Operating Sublease Remainder Of Fiscal Year FutureCashReceiptsFromOperatingSubleaseRemainderOfFiscalYear	313000	usd
CY2023Q1	abeo	Future Cash Receipts From Operating Sublease Next Twelve Months FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths	429000	usd
CY2023Q1	abeo	Future Cash Receipts From Operating Sublease Year Two FutureCashReceiptsFromOperatingSubleaseYearTwo	343000	usd
CY2023Q1	abeo	Future Cash Receipts From Operating Sublease FutureCashReceiptsFromOperatingSublease	1085000	usd
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	the Company’s stock underwent a 25:1 Reverse Stock Split
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1788000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.75
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1788000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.75
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000.0	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7000000.0	usd
CY2022Q4	abeo	Fair Value Warrant Liabilities FairValueWarrantLiabilities	9000000.0	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1788000	shares
CY2023Q1	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-12-21
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	770000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	862000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure

Files In Submission

Name	View Source	Status
0001493152-23-016278-index-headers.html	Edgar Link	pending
0001493152-23-016278-index.html	Edgar Link	pending
0001493152-23-016278.txt	Edgar Link	pending
0001493152-23-016278-xbrl.zip	Edgar Link	pending
abeo-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
abeo-20230331_cal.xml	Edgar Link	unprocessable
abeo-20230331_def.xml	Edgar Link	unprocessable
abeo-20230331_lab.xml	Edgar Link	unprocessable
abeo-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

2023 Q2 Form 10-Q Financial Statement

#000149315223016278 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO ABEONA THERAPEUTICS INC. Stock $abeo

2023 Q2 Form 10-Q Financial Statement

#000149315223016278 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo